Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

KaloBios grants rights to Sanofi Pasteur; rights returned

Executive Summary

KaloBios Pharmaceuticals (antibodies) has granted Sanofi Pasteur rights to develop and sell its investigational new biologic KB001 to treat or prevent Pseudomonas aeruginosa (Pa) infections.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register